X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Lupin Ltd with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ACTAVIS (US) - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 LUPIN LTD   ACTAVIS
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
ACTAVIS
Dec-14
LUPIN LTD/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,75017,702-   
Low Rs1,38410,798-   
Sales per share (Unadj.) Rs387.43,187.6-  
Earnings per share (Unadj.) Rs56.6-397.8-  
Cash flow per share (Unadj.) Rs76.8292.5-  
Dividends per share (Unadj.) Rs7.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs298.96,913.9-  
Shares outstanding (eoy) m451.58265.90-   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.04.5 90.5%   
Avg P/E ratio x27.7-35.8 -77.2%  
P/CF ratio (eoy) x20.448.7 41.8%  
Price / Book Value ratio x5.22.1 254.3%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m707,5133,789,034 18.7%   
No. of employees `00016.821.6 77.7%   
Total wages/salary Rs m28,4950-   
Avg. sales/employee Rs Th10,418.339,240.4 26.5%   
Avg. wages/employee Rs Th1,697.00-   
Avg. net profit/employee Rs Th1,523.0-4,896.8 -31.1%   
INCOME DATA
Net Sales Rs m174,943847,593 20.6%  
Other income Rs m1,065-2,115 -50.3%   
Total revenues Rs m176,008845,478 20.8%   
Gross profit Rs m44,931108,885 41.3%  
Depreciation Rs m9,122183,535 5.0%   
Interest Rs m1,52526,735 5.7%   
Profit before tax Rs m35,349-103,500 -34.2%   
Minority Interest Rs m-720-   
Prior Period Items Rs m830-   
Extraordinary Inc (Exp) Rs m0-7,592 0.0%   
Tax Rs m9,785-5,321 -183.9%   
Profit after tax Rs m25,575-105,771 -24.2%  
Gross profit margin %25.712.8 199.9%  
Effective tax rate %27.75.1 538.4%   
Net profit margin %14.6-12.5 -117.1%  
BALANCE SHEET DATA
Current assets Rs m119,542446,573 26.8%   
Current liabilities Rs m61,206325,683 18.8%   
Net working cap to sales %33.314.3 233.8%  
Current ratio x2.01.4 142.4%  
Inventory Days Days7658 131.0%  
Debtors Days Days9066 135.6%  
Net fixed assets Rs m131,660103,500 127.2%   
Share capital Rs m9030-   
"Free" reserves Rs m134,0730-   
Net worth Rs m134,9761,838,399 7.3%   
Long term debt Rs m56,478963,357 5.9%   
Total assets Rs m266,0733,369,180 7.9%  
Interest coverage x24.2-2.9 -841.9%   
Debt to equity ratio x0.40.5 79.8%  
Sales to assets ratio x0.70.3 261.4%   
Return on assets %10.2-2.3 -434.2%  
Return on equity %18.9-5.8 -329.3%  
Return on capital %19.3-3.0 -639.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m60,3780-   
CASH FLOW
From Operations Rs m41,148145,548 28.3%  
From Investments Rs m-25,287-348,498 7.3%  
From Financial Activity Rs m4,332195,806 2.2%  
Net Cashflow Rs m20,193-7,144 -282.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare LUPIN LTD With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare LUPIN LTD With: NATCO PHARMA  FULFORD INDIA  CIPLA  J.B.CHEMICALS  STRIDES SHASUN LTD  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views On News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Blueprint for Sensex 100,000(The 5 Minute Wrapup)

Feb 20, 2018

Investing in stocks is not about index gazing. There are 3-Ms that could help pick the right stocks.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 23, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE LUPIN LTD WITH

MARKET STATS